Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising global burden of diabetes, growing demand for advanced insulin delivery devices, and new product launches.
The diabetes management devices market is segmented as below:
By Product
- Blood glucose monitoring devices
- Insulin delivery systems
By Distribution Channel
- Offline
- Online
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the diabetes management devices market covers the following areas:
- Diabetes management devices market sizing
- Diabetes management devices market forecast
- Diabetes management devices market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape and an analysis of the key vendors.
The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
Executive Summary
The publisher recognizes the following companies as the key players in the global diabetes management devices market: Abbott Laboratories, ACON Laboratories Inc., B.Braun SE, Becton Dickinson and Co., Bionime Corp., Dexcom Inc., Eli Lilly and Co., F. Hoffmann La Roche Ltd., iHealth Labs Inc., Insulet Corp., LifeScan IP Holdings LLC, Medtronic Plc, Nemaura Medical Inc., Nipro Corp., Nova Biomedical Corp., Novo Nordisk AS, PHC Holdings Corp., Prodigy Diabetes Care LL, Tandem Diabetes Care Inc., and WellDoc Inc.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is growing focus on artificial pancreas.'
According to the report, one of the major drivers for this market is the rising global burden of diabetes.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape and a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- ACON Laboratories Inc.
- B.Braun SE
- Becton Dickinson and Co.
- Bionime Corp.
- Dexcom Inc.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- iHealth Labs Inc.
- Insulet Corp.
- LifeScan IP Holdings LLC
- Medtronic Plc
- Nemaura Medical Inc.
- Nipro Corp.
- Nova Biomedical Corp.
- Novo Nordisk AS
- PHC Holdings Corp.
- Prodigy Diabetes Care LL
- Tandem Diabetes Care Inc.
- WellDoc Inc.